相似文献
1
Methods of induced pluripotent stem cells for clinical application.
World J Stem Cells. 2015 Jan 26;7(1):116-25. doi: 10.4252/wjsc.v7.i1.116.
2
Age Is Relative-Impact of Donor Age on Induced Pluripotent Stem Cell-Derived Cell Functionality.
Front Cardiovasc Med. 2018 Jan 25;5:4. doi: 10.3389/fcvm.2018.00004. eCollection 2018.
3
Ten years of progress and promise of induced pluripotent stem cells: historical origins, characteristics, mechanisms, limitations, and potential applications.
PeerJ. 2018 May 11;6:e4370. doi: 10.7717/peerj.4370. eCollection 2018.
4
Systematic review of induced pluripotent stem cell technology as a potential clinical therapy for spinal cord injury.
Cell Transplant. 2013;22(4):571-617. doi: 10.3727/096368912X655208. Epub 2012 Aug 27.
5
iPSCs, aging and age-related diseases.
N Biotechnol. 2014 Sep 25;31(5):411-21. doi: 10.1016/j.nbt.2014.04.004. Epub 2014 Apr 29.
6
Reprogramming stem cells in regenerative medicine.
Smart Med. 2022 Dec 25;1(1):e20220005. doi: 10.1002/SMMD.20220005. eCollection 2022 Dec.
7
An Overview of Direct Somatic Reprogramming: The Ins and Outs of iPSCs.
Int J Mol Sci. 2016 Jan 21;17(1):141. doi: 10.3390/ijms17010141.
8
Reprint of "iPSCs, aging and age-related diseases".
N Biotechnol. 2015 Jan 25;32(1):169-79. doi: 10.1016/j.nbt.2014.11.002.
9
Future prospects for regenerated heart using induced pluripotent stem cells.
J Pharmacol Sci. 2014;125(1):1-5. doi: 10.1254/jphs.14r01cp. Epub 2014 Apr 16.
10
Induced pluripotent stem cells: applications in regenerative medicine, disease modeling, and drug discovery.
Front Cell Dev Biol. 2015 Feb 2;3:2. doi: 10.3389/fcell.2015.00002. eCollection 2015.
引用本文的文献
1
Hyaluronic acid stimulation of stem cells for cardiac repair: a cell-free strategy for myocardial infarct.
J Nanobiotechnology. 2024 Apr 4;22(1):149. doi: 10.1186/s12951-024-02410-x.
2
Contractile and Genetic Characterization of Cardiac Constructs Engineered from Human Induced Pluripotent Stem Cells: Modeling of Tuberous Sclerosis Complex and the Effects of Rapamycin.
Bioengineering (Basel). 2024 Feb 28;11(3):234. doi: 10.3390/bioengineering11030234.
3
Advances in Genetic Reprogramming: Prospects from Developmental Biology to Regenerative Medicine.
Curr Med Chem. 2024;31(13):1646-1690. doi: 10.2174/0929867330666230503144619.
4
An allied reprogramming, selection, expansion and differentiation platform for creating hiPSC on microcarriers.
Cell Prolif. 2022 Aug;55(8):e13256. doi: 10.1111/cpr.13256. Epub 2022 May 19.
5
Bioprocess Economic Modeling: Decision Support Tools for the Development of Stem Cell Therapy Products.
Bioengineering (Basel). 2022 Dec 11;9(12):791. doi: 10.3390/bioengineering9120791.
6
Pooled evidence from preclinical and clinical studies for stem cell-based therapy in ARDS and COVID-19.
Mol Cell Biochem. 2023 Jul;478(7):1487-1518. doi: 10.1007/s11010-022-04601-2. Epub 2022 Nov 17.
7
Recent Advances in Monitoring Stem Cell Status and Differentiation Using Nano-Biosensing Technologies.
Nanomaterials (Basel). 2022 Aug 25;12(17):2934. doi: 10.3390/nano12172934.
8
Treating intrauterine adhesion using conditionally reprogrammed physiological endometrial epithelial cells.
Stem Cell Res Ther. 2022 May 3;13(1):178. doi: 10.1186/s13287-022-02860-w.
9
Artificial Oocyte: Development and Potential Application.
Cells. 2022 Mar 28;11(7):1135. doi: 10.3390/cells11071135.
10
Current Biomaterial-Based Bone Tissue Engineering and Translational Medicine.
Int J Mol Sci. 2021 Sep 23;22(19):10233. doi: 10.3390/ijms221910233.
本文引用的文献
1
Abnormalities in human pluripotent cells due to reprogramming mechanisms.
Nature. 2014 Jul 10;511(7508):177-83. doi: 10.1038/nature13551. Epub 2014 Jul 2.
2
Transplanted terminally differentiated induced pluripotent stem cells are accepted by immune mechanisms similar to self-tolerance.
Nat Commun. 2014 May 30;5:3903. doi: 10.1038/ncomms4903.
3
Derivation of transgene-free human induced pluripotent stem cells from human peripheral T cells in defined culture conditions.
PLoS One. 2014 May 13;9(5):e97397. doi: 10.1371/journal.pone.0097397. eCollection 2014.
4
Human-induced pluripotent stem cells: potential for neurodegenerative diseases.
Hum Mol Genet. 2014 Sep 15;23(R1):R17-26. doi: 10.1093/hmg/ddu204. Epub 2014 May 13.
5
Concise review: pluripotent stem cell-based regenerative applications for failing β-cell function.
Stem Cells Transl Med. 2014 May;3(5):653-61. doi: 10.5966/sctm.2013-0184. Epub 2014 Mar 19.
6
A novel efficient feeder-free culture system for the derivation of human induced pluripotent stem cells.
Sci Rep. 2014 Jan 8;4:3594. doi: 10.1038/srep03594.
7
Differentiation-defective phenotypes revealed by large-scale analyses of human pluripotent stem cells.
Proc Natl Acad Sci U S A. 2013 Dec 17;110(51):20569-74. doi: 10.1073/pnas.1319061110. Epub 2013 Nov 20.
8
Reprogramming of human fibroblasts to pluripotency with lineage specifiers.
Cell Stem Cell. 2013 Sep 5;13(3):341-50. doi: 10.1016/j.stem.2013.06.019. Epub 2013 Jul 18.
9
Pluripotent stem cells induced from mouse somatic cells by small-molecule compounds.
Science. 2013 Aug 9;341(6146):651-4. doi: 10.1126/science.1239278. Epub 2013 Jul 18.
10
Immunologic and chemical targeting of the tight-junction protein Claudin-6 eliminates tumorigenic human pluripotent stem cells.
Nat Commun. 2013;4:1992. doi: 10.1038/ncomms2992.
Zotero 插件